{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-027025","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.467705+00:00","generated_at":"2026-05-17T07:00:14.190924+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Celcuity upsizes senior secured facility to $500M, receives $30M immediate funding","bullets":["Total facility increased to $500M ($350M committed + $150M discretionary); $30M funded, total outstanding $130M.","Adds $100M upon FDA approval of gedatolisib in 2L wild-type advanced breast cancer; $120M upon commercial milestones.","Maturity extended to Nov 1, 2029; interest-only period extended by 14 months, with possible 7-month FDA-approval extension.","Issued warrants for 50,537 shares to lenders; cashless exercise through tenth anniversary of Term D funding.","Funds will support NDA rolling submission via FDA's RTOR program, commercial launch prep, and strategic initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-027025","json":"https://secwatch.observer/filing/0001641172-25-027025.json","markdown":"https://secwatch.observer/filing/0001641172-25-027025.md","text":"https://secwatch.observer/filing/0001641172-25-027025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:00:14.190924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2216d5f8f23d53ebcc56432b3f7e570f7e2b5a94","claim":"Celcuity Inc. incurred term loan of $30.0 million Term D Loan with Oxford Finance LLC maturing November 1, 2029.","evidence_excerpt":"recognize the achievement of the Term D Milestone (as defined in the A&R Loan Agreement, as amended by the Third Amendment (the \"Amended A&R Loan Agreement\")) and provide for the immediate disbursement of the $30.0 million Term D Loan (as defined in the Amended A&R Loan Agreement)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$30.0 million Term D Loan"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Maturity","value":"November 1, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"77abd0c74943916e5a1d6475312a11c7b92f172e","claim":"Celcuity Inc. amended credit facility with Oxford Finance LLC maturing extend the maturity date of the term loans to November 1, 2029.","evidence_excerpt":"greement”) with Oxford Finance LLC, a Delaware limited liability company (“Oxford”), as collateral agent and a lender,","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Maturity","value":"extend the maturity date of the term loans to November 1, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"8cdc9aaa7f82e475a2fb6c159074a90e21872082","claim":"Celcuity Inc. amended credit facility of increase the size of the Term E Loan (as defined in the Amended A&R Loan Agreement) from $50.0 million to up to $100.0 m with Oxford Finance LLC maturing November 1, 2029.","evidence_excerpt":"increase the size of the Term E Loan (as defined in the Amended A&R Loan Agreement) from $50.0 million to up to $100.0 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"increase the size of the Term E Loan (as defined in the Amended A&R Loan Agreement) from $50.0 million to up to $100.0 m"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Maturity","value":"November 1, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"a8e659d28bf32d43ce8de8c36899d6fb0b1d4a6a","claim":"Celcuity Inc. amended term loan of three new $40.0 million Term F Loans with Oxford Finance LLC maturing November 1, 2029.","evidence_excerpt":"add three new $40.0 million Term F Loans (as defined in the Amended A&R Loan Agreement), which may only be drawn upon achievement of certain trailing three months’ product revenue thresholds","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"three new $40.0 million Term F Loans"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Maturity","value":"November 1, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"d657047dd632e7c17cfed72136988c38f37d646b","claim":"Celcuity Inc. amended term loan of replace the prior $45.0 million Term F Loan … with a new $150.0 million Term G Loan with Oxford Finance LLC maturing November 1, 2029.","evidence_excerpt":"replace the prior $45.0 million Term F Loan (as defined in the A&R Loan Agreement) with a new $150.0 million Term G Loan (as defined in the Amended A&R Loan Agreement)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"replace the prior $45.0 million Term F Loan … with a new $150.0 million Term G Loan"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Maturity","value":"November 1, 2029"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"33c7f830a9ed24afb0c8eb3f8c26dd8a0a97d02d","claim":"Celcuity Inc. issued 50,537 shares of warrant to Innovatus, Oxford, and certain of its affiliates.","evidence_excerpt":"the Company issued warrants to purchase an aggregate of 50,537 shares of the Company’s common stock to Innovatus, Oxford, and certain of its affiliates (the “Warrants”)","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"50,537 shares"},{"label":"Purchaser","value":"Innovatus, Oxford, and certain of its affiliates"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}